JP2016529253A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016529253A5 JP2016529253A5 JP2016533923A JP2016533923A JP2016529253A5 JP 2016529253 A5 JP2016529253 A5 JP 2016529253A5 JP 2016533923 A JP2016533923 A JP 2016533923A JP 2016533923 A JP2016533923 A JP 2016533923A JP 2016529253 A5 JP2016529253 A5 JP 2016529253A5
- Authority
- JP
- Japan
- Prior art keywords
- chem
- xaa
- 8aib
- seq
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002265 prevention Effects 0.000 claims 20
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 claims 8
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 8
- 230000009467 reduction Effects 0.000 claims 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 8
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 7
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 5
- 229940024606 amino acid Drugs 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 5
- 206010012601 diabetes mellitus Diseases 0.000 claims 5
- 208000008589 Obesity Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 208000002705 Glucose Intolerance Diseases 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 230000006872 improvement Effects 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 239000013067 intermediate product Substances 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 201000009104 prediabetes syndrome Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 208000014644 Brain disease Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 206010012655 Diabetic complications Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 230000006870 function Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- WLNMZODBWIWRGN-SSDOTTSWSA-N (2R)-2-amino-2-formyl-3-(1H-imidazol-5-yl)propanoic acid Chemical compound C(=O)[C@](N)(CC1=CNC=N1)C(=O)O WLNMZODBWIWRGN-SSDOTTSWSA-N 0.000 claims 1
- OQQDUMSNEFAJOO-MRVPVSSYSA-N (2r)-2-amino-2-(1h-imidazol-5-ylmethyl)-3-oxobutanoic acid Chemical compound CC(=O)[C@@](N)(C(O)=O)CC1=CN=CN1 OQQDUMSNEFAJOO-MRVPVSSYSA-N 0.000 claims 1
- CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 claims 1
- WTKYBFQVZPCGAO-LURJTMIESA-N (2s)-2-(pyridin-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CN=C1 WTKYBFQVZPCGAO-LURJTMIESA-N 0.000 claims 1
- SAAQPSNNIOGFSQ-LURJTMIESA-N (2s)-2-(pyridin-4-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=NC=C1 SAAQPSNNIOGFSQ-LURJTMIESA-N 0.000 claims 1
- MSECZMWQBBVGEN-LURJTMIESA-N (2s)-2-azaniumyl-4-(1h-imidazol-5-yl)butanoate Chemical compound OC(=O)[C@@H](N)CCC1=CN=CN1 MSECZMWQBBVGEN-LURJTMIESA-N 0.000 claims 1
- -1 (8Aib Chemical class 0.000 claims 1
- ACZFBYCNAVEFLC-YFKPBYRVSA-N (S)-3-(imidazol-5-yl)lactic acid Chemical compound OC(=O)[C@@H](O)CC1=CN=CN1 ACZFBYCNAVEFLC-YFKPBYRVSA-N 0.000 claims 1
- FVTVMQPGKVHSEY-UHFFFAOYSA-N 1-AMINOCYCLOBUTANE CARBOXYLIC ACID Chemical compound OC(=O)C1(N)CCC1 FVTVMQPGKVHSEY-UHFFFAOYSA-N 0.000 claims 1
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 102100040214 Apolipoprotein(a) Human genes 0.000 claims 1
- 101710115418 Apolipoprotein(a) Proteins 0.000 claims 1
- 102000007592 Apolipoproteins Human genes 0.000 claims 1
- 108010071619 Apolipoproteins Proteins 0.000 claims 1
- 200000000007 Arterial disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000031729 Bacteremia Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000014997 Crohn colitis Diseases 0.000 claims 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims 1
- 229930195721 D-histidine Natural products 0.000 claims 1
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000007530 Essential hypertension Diseases 0.000 claims 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010058179 Hypertensive emergency Diseases 0.000 claims 1
- 206010021518 Impaired gastric emptying Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 1
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 102000057248 Lipoprotein(a) Human genes 0.000 claims 1
- 108010033266 Lipoprotein(a) Proteins 0.000 claims 1
- 208000035180 MODY Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010038563 Reocclusion Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010049416 Short-bowel syndrome Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 1
- 206010071436 Systolic dysfunction Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- HRRYYCWYCMJNGA-ZETCQYMHSA-N alpha-methyl-L-histidine Chemical compound OC(=O)[C@](N)(C)CC1=CN=CN1 HRRYYCWYCMJNGA-ZETCQYMHSA-N 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 230000030135 gastric motility Effects 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 208000004104 gestational diabetes Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 229960002885 histidine Drugs 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000005857 malignant hypertension Diseases 0.000 claims 1
- 201000006950 maturity-onset diabetes of the young Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000037891 myocardial injury Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 206010042772 syncope Diseases 0.000 claims 1
- 230000035488 systolic blood pressure Effects 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- FCGQPGJZMYSYCJ-UHFFFAOYSA-N CC(C1CCC(CNN)CC1)=O Chemical compound CC(C1CCC(CNN)CC1)=O FCGQPGJZMYSYCJ-UHFFFAOYSA-N 0.000 description 2
- 0 CC(CCNI)OCCC(OC(C)(*)CC(N)=O)=* Chemical compound CC(CCNI)OCCC(OC(C)(*)CC(N)=O)=* 0.000 description 2
- LEUFZGSWQSPVGT-UHFFFAOYSA-N CC(C(CS(O)(=O)=O)NN)=O Chemical compound CC(C(CS(O)(=O)=O)NN)=O LEUFZGSWQSPVGT-UHFFFAOYSA-N 0.000 description 1
- KCEHUPIXDRDKQS-UHFFFAOYSA-N NC(CCC(C(O)=O)NN)=O Chemical compound NC(CCC(C(O)=O)NN)=O KCEHUPIXDRDKQS-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361866169P | 2013-08-15 | 2013-08-15 | |
| EP13180558.2 | 2013-08-15 | ||
| US61/866,169 | 2013-08-15 | ||
| EP13180558 | 2013-08-15 | ||
| PCT/EP2014/067413 WO2015022400A1 (en) | 2013-08-15 | 2014-08-14 | Glp-1 derivatives, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016529253A JP2016529253A (ja) | 2016-09-23 |
| JP2016529253A5 true JP2016529253A5 (enExample) | 2017-08-10 |
| JP6599863B2 JP6599863B2 (ja) | 2019-10-30 |
Family
ID=48985644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533923A Active JP6599863B2 (ja) | 2013-08-15 | 2014-08-14 | Ｇｌｐ−１誘導体及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10266577B2 (enExample) |
| EP (1) | EP3033112B1 (enExample) |
| JP (1) | JP6599863B2 (enExample) |
| CN (1) | CN105451776B (enExample) |
| WO (1) | WO2015022400A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| TW201716432A (zh) * | 2015-07-06 | 2017-05-16 | 諾佛 儂迪克股份有限公司 | 新穎肽與肽衍生物及其用途 |
| LT3393496T (lt) | 2015-12-23 | 2023-12-11 | The Johns Hopkins University | Ilgo veikimo glp-1r agonistas, kaip neurologinių ir neurodegeneracinių būklių terapija |
| EP3534962B1 (en) | 2016-11-07 | 2020-08-19 | Novo Nordisk A/S | Dchbs-active esters of peg compounds and their use |
| CN109248323B (zh) * | 2017-07-14 | 2023-09-08 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| RS65380B1 (sr) | 2017-08-24 | 2024-04-30 | Novo Nordisk As | Glp-1 kompozicije i njihova upotreba |
| JP2021514936A (ja) * | 2017-12-19 | 2021-06-17 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１ペプチドの可溶性 |
| EP4122954B1 (en) | 2018-04-05 | 2024-04-03 | Sun Pharmaceutical Industries Limited | Novel glp-1 analogues |
| WO2019200594A1 (zh) | 2018-04-19 | 2019-10-24 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| CN113214382B (zh) * | 2018-04-19 | 2024-01-19 | 杭州先为达生物科技股份有限公司 | 酰化的glp-1衍生物 |
| KR102379958B1 (ko) | 2018-05-04 | 2022-04-01 | 노보 노르디스크 에이/에스 | Gip 유도체 및 이의 용도 |
| US11753455B2 (en) | 2018-06-21 | 2023-09-12 | Novo Nordisk A/S | Compounds for treatment of obesity |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| CN110759991B (zh) * | 2019-12-09 | 2023-01-13 | 江苏师范大学 | 吉非罗齐-非洲爪蟾胰高血糖素样肽-1衍生物及其应用 |
| WO2022068920A1 (en) * | 2020-09-30 | 2022-04-07 | Beijing Ql Biopharmaceutical Co., Ltd. | Polypeptide conjugates and methods of uses |
| EP4314012A1 (en) * | 2021-03-24 | 2024-02-07 | Bristol-Myers Squibb Company | Immunomodulators |
| CN116891522B (zh) * | 2022-04-01 | 2024-05-14 | 南京知和医药科技有限公司 | 一种长效胰高血糖素样肽-1衍生物及其制备方法和用途 |
| WO2024179606A1 (zh) * | 2023-03-02 | 2024-09-06 | 甘李药业股份有限公司 | 一种glp-1化合物的医药用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0944648T3 (da) | 1996-08-30 | 2007-07-02 | Novo Nordisk As | GLP-1 derivater |
| EP1100530B1 (en) | 1998-07-31 | 2003-10-08 | Novo Nordisk A/S | In-vitro stimulation of beta cell proliferation |
| EP1542712A2 (en) | 2001-06-01 | 2005-06-22 | Eli Lilly And Company | Glp-1 formulations with protracted time action |
| NZ534125A (en) | 2002-02-20 | 2006-11-30 | Emisphere Tech Inc | A formulation comprising a GLP-1 compound and a delivery agent |
| EP1670515A2 (en) | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| US20060286129A1 (en) | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| WO2008028974A1 (en) * | 2006-09-08 | 2008-03-13 | Novo Nordisk A/S | Methods of optimizing chromatographic separation of polypeptides |
| WO2011073328A1 (en) | 2009-12-16 | 2011-06-23 | Novo Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| WO2012062803A1 (en) * | 2010-11-09 | 2012-05-18 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| EP3225631B1 (en) | 2011-04-12 | 2019-01-09 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| JP6250034B2 (ja) * | 2012-05-08 | 2017-12-20 | ノヴォ ノルディスク アー／エス | 二重アシル化されたｇｌｐ−１誘導体 |
-
2014
- 2014-08-14 CN CN201480045339.1A patent/CN105451776B/zh active Active
- 2014-08-14 JP JP2016533923A patent/JP6599863B2/ja active Active
- 2014-08-14 EP EP14752614.9A patent/EP3033112B1/en active Active
- 2014-08-14 WO PCT/EP2014/067413 patent/WO2015022400A1/en not_active Ceased
- 2014-08-14 US US14/909,543 patent/US10266577B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016529253A5 (enExample) | ||
| JP2016523243A5 (enExample) | ||
| JP2017105819A5 (enExample) | ||
| JP2018505859A5 (enExample) | ||
| JP2019513126A5 (enExample) | ||
| JP2014501712A5 (enExample) | ||
| JP2013543853A5 (enExample) | ||
| JP2014529629A5 (enExample) | ||
| RU2013148921A (ru) | Дважды ацилированные производные glp-1 | |
| Han et al. | Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates | |
| JP6379300B2 (ja) | ＧＬＰ及び免疫グロブリンハイブリッドＦｃ融合ポリペプチド及びその用途 | |
| JP2023071869A (ja) | グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト | |
| JP2015517477A5 (enExample) | ||
| AU2011247824B2 (en) | Glucagon-like peptide-1 analogue and use thereof | |
| JP2015517478A5 (enExample) | ||
| EP2729493A1 (en) | Novel compounds and their effects on feeding behaviour | |
| JP2015517459A5 (enExample) | ||
| RU2012128547A (ru) | Дважды ацилированные производные glp-1 | |
| US20100305139A1 (en) | Method of treating abnormal lipid metabolism | |
| JP2007519642A5 (enExample) | ||
| CN107205949A (zh) | 包含片芯和立即释放包衣的用于口服glp‑1给药的药物组合物 | |
| Jin et al. | GPCRs involved in metabolic diseases: pharmacotherapeutic development updates | |
| JP2013510167A (ja) | ストレスコピン様ペプチドによる心不全の治療方法 | |
| Xu et al. | Myeloid-derived growth factor and its effects on cardiovascular and metabolic diseases | |
| CN107987152A (zh) | 霉酚酸-非洲爪蟾胰高血糖素样肽-1缀合肽及其用途 |